Macomics, an immuno-oncology company, secures £3.2 million seed funding from Epidarex Capital & the Scottish Investment Bank
July 14, 2020
Novel immuno-therapies to overcome the resistance of existing cancer treatments Builds on the world-leading research into tumour associated macrophages (TAMs) Robert Haigh joins as CEO